• Wondering if Intellia Therapeutics at around US$13.71 is offering value or just volatility? This article walks through what the current price may be implying about the stock.
• The stock has returned 1.7% over the last 7 days, 1.2% over 30 days, 48.9% year to date and 65.6% over the past year, while longer term 3 year and 5 year returns of 69.3% and 77.5% declines show how sentiment around the stock has shifted over time.
• Recent headlines around Intellia Therapeutics have focused on its position in gene editing and broader interest in biotech, which often draws attention to companies that are still investing heavily in research rather than generating consistent profits. These themes help frame why the stock can experience sharp moves as investors reassess risk and potential.
• Right now Intellia Therapeutics holds a valuation score of 3/6. The next sections will walk through what different valuation methods suggest about the stock, before finishing with a broader approach that can help you put those numbers into context.

Approach 1: Intellia Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model looks at the cash Intellia Therapeutics is expected to generate in the future and then discounts those projected cash flows back to today to estimate what the stock might be worth now.

For Intellia Therapeutics, the latest twelve month free cash flow is a loss of about $403.5 million. Analysts and model estimates then project free cash flow to move through a mix of negative and positive figures, reaching $372.9 million by 2030. Beyond the analyst horizon, Simply Wall St extrapolates further out year by year using its 2 Stage Free Cash Flow to Equity approach, all in $.

When all those projected cash flows are discounted back, the DCF model suggests an intrinsic value of about $145.53 per share. Compared with a current share price around $13.71, this indicates a potential undervaluation of 90.6% based on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Intellia Therapeutics is undervalued by 90.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Intellia Therapeutics Price vs Sales

For companies that are not consistently profitable, P/S is often more useful than P/E because it compares the stock price with current revenue rather than earnings that may still be negative or volatile.

Investors usually expect higher P/S ratios when they see stronger growth potential and are comfortable with higher risk, and lower P/S ratios when growth expectations are more muted or risks feel elevated. So what really matters is how Intellia Therapeutics’ current P/S stacks up against reasonable reference points.

Intellia Therapeutics is trading on a P/S of 28.31x. This sits above the Biotechs industry average P/S of 10.93x and below the peer group average of 32.53x, which indicates the stock is priced at a premium to the wider industry but not to the most directly comparable companies.

Simply Wall St’s Fair Ratio is a proprietary estimate of what a “normal” P/S could be for Intellia Therapeutics, given its earnings growth profile, industry, profit margins, market cap and risk factors. Because it adjusts for these company specific drivers, it can be more tailored than a simple comparison with peers or industry averages.

Here, the Fair Ratio for Intellia Therapeutics is 0.04x, which is far below the current P/S of 28.31x. On this metric, the stock screens as clearly overvalued.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Intellia Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and that is through Narratives, which are simple stories you create about a company that link your view of its future revenue, earnings and margins to a financial forecast and then to a fair value, all within an easy tool on Simply Wall St’s Community page that millions of investors already use.

With a Narrative, you can compare your fair value for Intellia Therapeutics to the current share price to help decide whether it looks appealing or stretched for your own goals, and your view automatically updates when new information such as news or earnings is added to the platform.

For example, one investor might build a Narrative closer to the US$106 high analyst target with very strong revenue and earnings assumptions. Another might anchor nearer the US$5 low target with more cautious expectations. Seeing those side by side makes it clear how different stories about the same stock can lead to very different fair values.

Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.